These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
468 related articles for article (PubMed ID: 30004583)
1. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis. Takamura S; Takahashi A; Inoue Y; Teraki Y J Dermatol; 2018 Sep; 45(9):1130-1134. PubMed ID: 30004583 [TBL] [Abstract][Full Text] [Related]
3. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Gisondi P; Conti A; Galdo G; Piaserico S; De Simone C; Girolomoni G Br J Dermatol; 2013 May; 168(5):1124-7. PubMed ID: 23320916 [TBL] [Abstract][Full Text] [Related]
4. Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis. Tan E; Baker C; Foley P Australas J Dermatol; 2013 Nov; 54(4):259-63. PubMed ID: 24164178 [TBL] [Abstract][Full Text] [Related]
5. Safety of biologics in psoriasis. Kamata M; Tada Y J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369 [TBL] [Abstract][Full Text] [Related]
6. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis. Wong IT; Shojania K; Dutz J; Tsao NW Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527 [TBL] [Abstract][Full Text] [Related]
7. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis. Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737 [TBL] [Abstract][Full Text] [Related]
8. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective. Ross C; Marshman G; Grillo M; Stanford T Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697 [TBL] [Abstract][Full Text] [Related]
11. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics. Asahina A; Umezawa Y; Yanaba K; Nakagawa H J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718 [TBL] [Abstract][Full Text] [Related]
12. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. Torres T; Puig L; Vender R; Lynde C; Piaserico S; Carrascosa JM; Gisondi P; Daudén E; Conrad C; Mendes-Bastos P; Ferreira P; Leite L; Lu JD; Valerio J; Bruni M; Messina F; Nidegger A; Llamas-Velasco M; Del Alcazar E; Mufti A; White K; Caldarola G; Teixeira L; Romanelli P; Desai K; Gkalpakiotis S; Romanelli M; Yeung J; Nogueira M; Chiricozzi A Am J Clin Dermatol; 2021 Jul; 22(4):567-579. PubMed ID: 33786754 [TBL] [Abstract][Full Text] [Related]
13. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study. Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039 [TBL] [Abstract][Full Text] [Related]
14. Japanese guidance for use of biologics for psoriasis (the 2019 version). Saeki H; Terui T; Morita A; Sano S; Imafuku S; Asahina A; Komine M; Etoh T; Igarashi A; Torii H; Abe M; Nakagawa H; Watanabe A; Yotsuyanagi H; Ohtsuki M; J Dermatol; 2020 Mar; 47(3):201-222. PubMed ID: 31916326 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study. Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H; Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927 [TBL] [Abstract][Full Text] [Related]
16. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry. Egeberg A; Iversen L; Gniadecki R; Hvid L; Dam TN; Bryld LE; Skov L J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1183-1187. PubMed ID: 28273375 [TBL] [Abstract][Full Text] [Related]
18. Elderly psoriatic patients under biological therapies: an Italian experience. Ricceri F; Bardazzi F; Chiricozzi A; Dapavo P; Ferrara F; Mugheddu C; Romanelli M; Rongioletti F; Prignano F J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):143-146. PubMed ID: 29906311 [TBL] [Abstract][Full Text] [Related]
19. Secukinumab: a review in moderate to severe plaque psoriasis. Garnock-Jones KP Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK. Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]